Move to topTop
January 31, 2017

TOKYO, JAPAN - Jan. 31, 2017 - Terumo Corporation (TSE: 4543) announced today that its Yangon Branch opened for business in January 2017.

In Myanmar, economic growth has been strong1 and healthcare market has been expanding since the country's transition from military rule to a civilian government in 2011. Growth is projected to continue in the future, but maintenance of healthcare systems and facilities has been falling behind.2

Terumo began doing business in Myanmar in the 1990s,3 and has continuously engaged in commercial activities in the country since that time. As a result, Terumo now has substantial market shares in Myanmar for a wide range of products, including interventional systems, oxygenators, blood bags, blood glucose monitors, and infusion systems. By opening a branch in Yangon, the country's largest city, Terumo intends to establish more locally based operations and expand its business while also aiming to contribute to the development of medical technologies in the country by offering healthcare training and other initiatives.

Overview of the Yangon Branch

Name: Terumo Singapore Pte. Ltd. (Yangon Branch)
Location: Yangon, Myanmar
Date of establishment: June 23, 2016
Date of opening: January 9, 2017
Number of employees: 3 (As of January, 2017)
  • 1.

    Real GDP is forecast to grow between 6 - 9% annually according to the International Monetary Fund's World Economic Outlook Database

  • 2.

    According to a report on global healthcare conditions published by Japan's Ministry of Foreign Affairs

  • 3.

    Sales are mainly carried out through local sales agents

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.